Noxopharm Limited (NOX)

Overview

Noxopharm Limited is an Australian biotech firm focused on the discovery and development of treatments for cancer and inflammation, alongside the research into mRNA vaccines. Established in 2015 and based in Glenhaven, Australia, the company is at the forefront of creating innovative therapies aimed at addressing unmet medical needs, particularly in the realm of oncology. Through its proprietary technologies and platforms, Noxopharm is dedicated to advancing the medical field with solutions intended both for improving patient outcomes and offering new avenues for the treatment of difficult diseases.

Products and Services

• Veyonda: A formulation of idronoxil designed primarily for the treatment of solid tumors. Noxopharm is actively developing Veyonda with the hope of providing a new solution for patients battling with various forms of cancer.
• LuPIN Program: This development combines therapy of Veyonda and 177Lu-PSMA-617, targeting the treatment of late-stage prostate cancer. It signifies a specialized approach in treating one of the most common types of cancer affecting men globally.
• IONIC Program: In collaboration with the Bristol Myers Squibb checkpoint inhibitor Opdivo, the IONIC program involves a strategic combination with Veyonda for the treatment of different solid tumor types. This initiative reflects Noxopharm's commitment to diversifying its therapeutic strategies to benefit a wider patient population.
• NOXCOVID Program: A targeted study involving dose escalation and dose expansion of NOX66 for the potential treatment of COVID-19 infection. This program underscores Noxopharm's flexibility and adaptability in addressing emergent global health crises through innovative therapeutic applications.
• Chroma Technology Platform: Aimed at developing the CRO-67 dual-cell therapy drug specifically for pancreatic cancer, along with various molecules for treating autoimmune disease and hyperinflammatory conditions. This platform is indicative of Noxopharm's dedication to tackling some of the most challenging diseases with cutting-edge biomedical technology.
• Sofra Platform: Focuses on the development of immunomodulators for mRNA vaccines and mRNA therapeutics, as well as for the treatment of autoimmune diseases. The Sofra platform represents Noxopharm's investment in the future of mRNA technology, potentially revolutionizing how diseases are treated and prevented.